Eledon Pharmaceuticals
ELDN
42 hedge funds and large institutions have $2.43M invested in Eledon Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 7 closing their positions.
138% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 8
5% less funds holding
Funds holding: 44 → 42 (-2)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
43% less capital invested
Capital invested by funds: $4.26M → $2.43M (-$1.84M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$264K |
| 2 |
D.E. Shaw & Co
New York
|
+$183K |
| 3 |
Renaissance Technologies
New York
|
+$169K |
| 4 |
State Street
Boston,
Massachusetts
|
+$68.6K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$64.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$492K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$417K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$303K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$61.7K |
| 5 |
SIM
Spark Investment Management
New York
|
-$54K |
ELDN Hedge Fund Activity: Q4 2016 in Review
42 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2016, worth a combined $2.43M — down 43% from $4.26M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ELDN and 6 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 19 added.
The largest buyer was Vanguard Group, adding an estimated $264K. The largest seller was Sabby Management, exiting entirely with an estimated $492K sold.
- 42 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2016, down from 44 in Q3 2016.
- Funds reported $2.43M of Eledon Pharmaceuticals stock for Q4 2016, down 43% quarter-over-quarter.
- 6 funds opened new Eledon Pharmaceuticals positions in Q4 2016 and 7 closed out, a net change of -1 holder.
- The largest Eledon Pharmaceuticals buyer in Q4 2016 was Vanguard Group, an estimated $264K added.
- The largest Eledon Pharmaceuticals seller in Q4 2016 was Sabby Management, an estimated $492K sold.
Based on aggregated 13F filings for Q4 2016.